{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:40:12Z","timestamp":1791412812293,"version":"4.3.3"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia","award":["ISP23-101"],"award-info":[{"award-number":["ISP23-101"]}]},{"name":"Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia","award":["ISP23-101"],"award-info":[{"award-number":["ISP23-101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10555-025-10244-8","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:43:51Z","timestamp":1737773031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies"],"prefix":"10.1007","volume":"44","author":[{"given":"Sarra","family":"Mestiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Moustafa Abo","family":"El-Ella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Khatoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin Mansor","family":"Mathkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafiul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"10244_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209\u2013249.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10244_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10147-021-02108-2","volume":"27","author":"R Sharma","year":"2022","unstructured":"Sharma, R. (2022). Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. International Journal of Clinical Oncology, 27, 665\u2013675.","journal-title":"International Journal of Clinical Oncology"},{"issue":"2019","key":"10244_CR3","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics. CA: A Cancer Journal for Clinicians, 69(2019), 7\u201334.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10244_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fmed.2020.00090","volume":"7","author":"T Berghmans","year":"2020","unstructured":"Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. M. (2020). Immunotherapy: From advanced NSCLC to early stages, an evolving concept. Frontiers in Medicine (Lausanne), 7, 90.","journal-title":"Frontiers in Medicine (Lausanne)"},{"key":"10244_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168, 707\u2013723.","journal-title":"Cell"},{"key":"10244_CR6","doi-asserted-by":"publisher","unstructured":"Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V., Gul, A. R. Z., Uddin, S., Homsi, M. U. A., & Dermime, S. (2020). Evolving dynamic biomarkers for prediction of immune responses to checkpoint inhibitors in cancer. Advances in Precision Medicine Oncology. https:\/\/doi.org\/10.5772\/intechopen.96494","DOI":"10.5772\/intechopen.96494"},{"key":"10244_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/biomedicines6030076","volume":"6","author":"L Pilla","year":"2018","unstructured":"Pilla, L., & Maccalli, C. (2018). Immune profiling of cancer patients treated with immunotherapy: Advances and challenges. Biomedicines, 6, 76.","journal-title":"Biomedicines"},{"key":"10244_CR8","doi-asserted-by":"publisher","first-page":"1157100","DOI":"10.3389\/fimmu.2023.1157100","volume":"14","author":"A Raza","year":"2023","unstructured":"Raza, A., Mohsen, R., Kanbour, A., Zar Gul, A. R., Philip, A., Vijayakumar, S., Hydrose, S., Prabhu, K. S., Al-Suwaidi, A. K., Inchakalody, V. P., Merhi, M., Abo El-Ella, D. M., Tauro, M. A., Akbar, S., Al-Bozom, I., Abualainin, W., Al-Abdulla, R., Sirriya, S. A., Hassnad, S., \u2026 Demime, S. (2023). Serum immune mediators as novel predictors of response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression. Frontiers in Immunology, 14, 1157100.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR9","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/cancers12123851","volume":"12","author":"R Pathak","year":"2020","unstructured":"Pathak, R., Pharaon, R. R., Mohanty, A., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020). Acquired resistance to PD-1\/PD-L1 blockade in lung cancer: Mechanisms and patterns of failure. Cancers (Basel), 12, 3851.","journal-title":"Cancers (Basel)"},{"key":"10244_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","volume":"25","author":"X Ye","year":"2015","unstructured":"Ye, X., & Weinberg, R. A. (2015). Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends in Cell Biology, 25, 675\u2013686.","journal-title":"Trends in Cell Biology"},{"key":"10244_CR11","doi-asserted-by":"publisher","first-page":"1234850","DOI":"10.1126\/science.1234850","volume":"342","author":"MA Nieto","year":"2013","unstructured":"Nieto, M. A. (2013). Epithelial plasticity: A common theme in embryonic and cancer cells. Science, 342, 1234850.","journal-title":"Science"},{"key":"10244_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 14, 611\u2013629.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10244_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi, Z. D., Pang, K., Wu, Z. X., Dong, Y., Hao, L., Qin, J. X., Wang, W., Chen, Z. S., & Han, C. H. (2023). Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies. Signal Transduction and Targeted Therapy, 8, 113.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10244_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41392-020-00313-5","volume":"5","author":"S Qin","year":"2020","unstructured":"Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 5, 228.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10244_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","volume":"30","author":"B Bakir","year":"2020","unstructured":"Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020). EMT, MET, plasticity, and tumor metastasis. Trends in Cell Biology, 30, 764\u2013776.","journal-title":"Trends in Cell Biology"},{"key":"10244_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., Nilsson, M. B., Gudikote, J., Tran, H., Cardnell, R. J., Bearss, D. J., Warner, S. L., Foulks, J. M., Kanner, S. B., Gandhi, V., \u2026 Heymach, J. V. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research, 19, 279\u2013290.","journal-title":"Clinical Cancer Research"},{"key":"10244_CR17","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41598-018-21061-1","volume":"8","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W. M., Lee, K., & Cruz, M. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Scientific reports, 8, 2918.","journal-title":"Scientific reports"},{"key":"10244_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41416-024-02698-4","volume":"131","author":"H Jeong","year":"2024","unstructured":"Jeong, H., Koh, J., Kim, S., Song, S. G., Lee, S. H., Jeon, Y., Lee, C. H., Keam, B., Lee, S. H., Chung, D. H., & Jeon, Y. K. (2024). Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. British journal of cancer, 131, 23\u201336.","journal-title":"British journal of cancer"},{"key":"10244_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","volume":"83","author":"L Guo","year":"2022","unstructured":"Guo, L., Lee, Y. T., Zhou, Y., & Huang, Y. (2022). Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Seminars in Cancer Biology, 83, 487\u2013502.","journal-title":"Seminars in Cancer Biology"},{"key":"10244_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41419-017-0120-6","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang, L., Dong, X., Ren, Y., Luo, J., Liu, P., Su, D., & Yang, X. (2018). Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN\/AKT signaling pathway. Cell Death & Disease, 9, 129.","journal-title":"Cell Death & Disease"},{"key":"10244_CR21","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.3390\/cancers12123674","volume":"12","author":"R Hass","year":"2020","unstructured":"Hass, R., von der Ohe, J., & Ungefroren, H. (2020). The intimate relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to be exploited for therapeutic purposes. Cancers (Basel), 12, 3674.","journal-title":"Cancers (Basel)"},{"key":"10244_CR22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41388-018-0482-y","volume":"38","author":"ZA Yochum","year":"2019","unstructured":"Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O\u2019Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H., Rudin, C. M., Tran, P. T., & Burns, T. F. (2019). Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene, 38, 656\u2013670.","journal-title":"Oncogene"},{"key":"10244_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","volume":"6","author":"F Casciello","year":"2015","unstructured":"Casciello, F., Windloch, K., Gannon, F., & Lee, J. S. (2015). Functional role of G9a histone methyltransferase in cancer. Frontiers in Immunology, 6, 487.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR24","doi-asserted-by":"publisher","first-page":"9636","DOI":"10.1074\/jbc.M109.062588","volume":"285","author":"J Huang","year":"2010","unstructured":"Huang, J., Dorsey, J., Chuikov, S., Zhang, X., Jenuwein, T., Reinberg, D., & Berger, S. L. (2010). G9a and Glp methylate lysine 373 in the tumor suppressor p53. Journal of Biological Chemistry, 285, 9636\u20139641.","journal-title":"Journal of Biological Chemistry"},{"key":"10244_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/19336918.2019.1638689","volume":"13","author":"Y Hu","year":"2019","unstructured":"Hu, Y., Zheng, Y., Dai, M., Wu, J., Yu, B., Zhang, H., Kong, W., Wu, H., & Yu, X. (2019). Snail2 induced E-cadherin suppression and metastasis in lung carcinoma facilitated by G9a and HDACs. Cell Adhesion & Migration, 13, 285\u2013292.","journal-title":"Cell Adhesion & Migration"},{"key":"10244_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/jcb.24019","volume":"113","author":"M Xie","year":"2012","unstructured":"Xie, M., Zhang, L., He, C. S., Xu, F., Liu, J. L., Hu, Z. H., Zhao, L. P., & Tian, Y. (2012). Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of Cellular Biochemistry, 113, 1501\u20131513.","journal-title":"Journal of Cellular Biochemistry"},{"key":"10244_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678333","volume":"11","author":"X Zheng","year":"2021","unstructured":"Zheng, X., Yu, C., & Xu, M. (2021). Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy. Frontiers in Oncology, 11, 678333.","journal-title":"Frontiers in Oncology"},{"key":"10244_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jtho.2016.05.025","volume":"11","author":"Y Shintani","year":"2016","unstructured":"Shintani, Y., Fujiwara, A., Kimura, T., Kawamura, T., Funaki, S., Minami, M., & Okumura, M. (2016). IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling. Journal of Thoracic Oncology, 11, 1482\u20131492.","journal-title":"Journal of Thoracic Oncology"},{"key":"10244_CR29","doi-asserted-by":"publisher","first-page":"42031","DOI":"10.18632\/oncotarget.9662","volume":"7","author":"RI Fernando","year":"2016","unstructured":"Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C. (2016). IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget, 7, 42031\u201342044.","journal-title":"Oncotarget"},{"key":"10244_CR30","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou, Y., Diao, L., Cuentas, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., Rodriguez, J. C., Hwu, P., Wistuba, J. V., II., & Heymach, D.L. Gibbons. (2016). Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research, 22, 3630\u20133642.","journal-title":"Clinical Cancer Research"},{"key":"10244_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","volume":"32","author":"T Condamine","year":"2011","unstructured":"Condamine, T., & Gabrilovich, D. I. (2011). Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends in Immunology, 32, 19\u201325.","journal-title":"Trends in Immunology"},{"key":"10244_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ncb3355","volume":"18","author":"T Welte","year":"2016","unstructured":"Welte, T., Kim, I. S., Tian, L., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A., Xie, G., Kurley, S., Nguyen, T., Liao, L., Dobrolecki, L. E., Pang, L., Mo, Q., Edwards, D. P., Huang, S., Xin, L., \u2026 Zhang, X. H. (2016). Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature Cell Biology, 18, 632\u2013644.","journal-title":"Nature Cell Biology"},{"key":"10244_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031524","volume":"7","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender, Z. G., Sun, J., Mishalian, I., Singhal, S., Cheng, G., Kapoor, V., Horng, W., Fridlender, G., Bayuh, R., Worthen, G. S., & Albelda, S. M. (2012). Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE, 7, e31524.","journal-title":"PLoS ONE"},{"key":"10244_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011). Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews Immunology, 11, 519\u2013531.","journal-title":"Nature Reviews Immunology"},{"key":"10244_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.semcancer.2013.02.001","volume":"23","author":"F Donskov","year":"2013","unstructured":"Donskov, F. (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Seminars in Cancer Biology, 23, 200\u2013207.","journal-title":"Seminars in Cancer Biology"},{"key":"10244_CR36","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41598-018-21061-1","volume":"8","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W. M., Lee, K., & Cruz, M. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Science and Reports, 8, 2918.","journal-title":"Science and Reports"},{"key":"10244_CR37","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., Obyrne, K., & Kulasinghe, A. (2022). Immune checkpoint inhibitors in cancer therapy. Current oncology (Toronto, Ont.), 29, 3044\u20133060.","journal-title":"Current oncology (Toronto, Ont.)"},{"key":"10244_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P., & G\u00f6genur, I. (2021). Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 124, 359\u2013367.","journal-title":"British Journal of Cancer"},{"key":"10244_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay, R. E., Richardson, E. K., & Toh, H. C. (2021). Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Therapy, 28, 5\u201317.","journal-title":"Cancer Gene Therapy"},{"key":"10244_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-023-10502-4","volume":"23","author":"X Du","year":"2023","unstructured":"Du, X., Wen, S., Shi, R., Xia, J., Wang, R., Zhang, Y., Pan, B., Wu, X., Zhu, W., Feng, J., Wang, X., & Shen, B. (2023). Peripheral blood lymphocytes differentiation patterns in responses \/ outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: A retrospective study. BMC Cancer, 23, 83.","journal-title":"BMC Cancer"},{"key":"10244_CR41","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.21037\/jtd-19-3414a","volume":"12","author":"AB Schulze","year":"2020","unstructured":"Schulze, A. B., Evers, G., Gorlich, D., Mohr, M., Marra, A., Hillejan, L., Rehkamper, J., Schmidt, L. H., & Heitkotter, B. (2020). Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer. Journal of Thoracic Disease, 12, 1824\u20131842.","journal-title":"Journal of Thoracic Disease"},{"key":"10244_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1078-0432.CCR-13-2573","volume":"20","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y., & Chen, L. (2014). CD137 as a biomarker for tumor-reactive T cells: Finding gold in the desert. Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research, 20, 3\u20135.","journal-title":"Clinical Cancer Research : An Official Journal of the American Association for Cancer Research"},{"key":"10244_CR43","first-page":"1027","volume":"28","author":"IG Zizzari","year":"2022","unstructured":"Zizzari, I. G., Di Filippo, A., Botticelli, A., Strigari, L., Pernazza, A., Rullo, E., Pignataro, M. G., Ugolini, A., Scirocchi, F., Di Pietro, F. R., Rossi, E., Gelibter, A., Schinzari, G., D\u2019Amati, G., Rughetti, A., Marchetti, P., Nuti, M., & Napoletano, C. (2022). Circulating CD137+ T cells correlate with improved response to anti-PD1 immunotherapy in patients with cancer, Clinical cancer research\u202f: An official journal of the American Association for. Cancer Research, 28, 1027\u20131037.","journal-title":"Cancer Research"},{"key":"10244_CR44","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-20-4231","volume":"26","author":"KH Kim","year":"2020","unstructured":"Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J. M., Lee, S. H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S. H., Park, K., Ahn, M. J., & Shin, E. C. (2020). Correction: The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors. Clinical cancer research\u202f: An official journal of the American Association for Cancer Research, 26, 6610.","journal-title":"Clinical cancer research : An official journal of the American Association for Cancer Research"},{"key":"10244_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12967-024-05142-6","volume":"22","author":"A Gelibter","year":"2024","unstructured":"Gelibter, A., Asquino, A., Strigari, L., Zizzari, I. G., Tuosto, L., Scirocchi, F., Pace, A., Siringo, M., Tramontano, E., Bianchini, S., Bellati, F., Botticelli, A., Paoli, D., Santini, D., Nuti, M., Rughetti, A., & Napoletano, C. (2024). CD137(+) and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line. Journal of Translational Medicine, 22, 329.","journal-title":"Journal of Translational Medicine"},{"key":"10244_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q., Sun, Z., & Chen, L. (2020). Memory T cells: Strategies for optimizing tumor immunotherapy. Protein & cell, 11, 549\u2013564.","journal-title":"Protein & cell"},{"key":"10244_CR47","doi-asserted-by":"publisher","first-page":"1061255","DOI":"10.3389\/fimmu.2023.1061255","volume":"14","author":"S Mestiri","year":"2023","unstructured":"Mestiri, S., Merhi, M., Inchakalody, V. P., Taib, N., Smatti, M. K., Ahmad, F., Raza, A., Ali, F. H., Hydrose, S., Fernandes, Q., Ansari, A. W., Sahir, F., Al-Zaidan, L., Jalis, M., Ghoul, M., Allahverdi, N., Al Homsi, M. U., Uddin, S., Jeremijenko, A. M., \u2026 Dermime, S. (2023). Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. Frontiers in Immunology, 14, 1061255.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR48","doi-asserted-by":"publisher","first-page":"1073457","DOI":"10.3389\/fonc.2022.1073457","volume":"12","author":"N Dutta","year":"2022","unstructured":"Dutta, N., Rohlin, A., Eklund, E. A., Magnusson, M. K., Nilsson, F., Aky\u00fcrek, L. M., Torstensson, P., Sayin, V. I., Lundgren, A., Hallqvist, A., & Raghavan, S. (2022). Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. Frontiers in oncology, 12, 1073457.","journal-title":"Frontiers in oncology"},{"key":"10244_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152391","volume":"228","author":"J Lao","year":"2023","unstructured":"Lao, J., Xu, H., Liang, Z., Luo, C., Shu, L., Xie, Y., Wu, Y., Hao, Y., & Yuan, Y. (2023). Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer. Immunobiology, 228, 152391.","journal-title":"Immunobiology"},{"key":"10244_CR50","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","volume":"9","author":"N Manjarrez-Ordu\u00f1o","year":"2018","unstructured":"Manjarrez-Ordu\u00f1o, N., Menard, L. C., Kansal, S., Fischer, P., Kakrecha, B., Jiang, C., Cunningham, M., Greenawalt, D., Patel, V., Yang, M., Golhar, R., Carman, J. A., Lezhnin, S., Dai, H., Kayne, P. S., Suchard, S. J., Bernstein, S. H., & Nadler, S. G. (2018). Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Frontiers in Immunology, 9, 1613.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR51","doi-asserted-by":"publisher","first-page":"10731","DOI":"10.2147\/CMAR.S228887","volume":"11","author":"A Verma","year":"2019","unstructured":"Verma, A., Mathur, R., Farooque, A., Kaul, V., Gupta, S., & Dwarakanath, B. S. (2019). T-regulatory cells in tumor progression and therapy. Cancer Management and Research, 11, 10731\u201310747.","journal-title":"Cancer Management and Research"},{"key":"10244_CR52","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00262-021-03018-y","volume":"71","author":"DH Kang","year":"2022","unstructured":"Kang, D. H., Chung, C., Sun, P., Lee, D. H., Lee, S. I., Park, D., Koh, J. S., Kim, Y., Yi, H. S., & Lee, J. E. (2022). Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Cancer Immunology, Immunotherapy\u202f: CII, 71, 579\u2013588.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10244_CR53","doi-asserted-by":"publisher","first-page":"18994","DOI":"10.1038\/s41598-020-76130-1","volume":"10","author":"J Koh","year":"2020","unstructured":"Koh, J., Hur, J. Y., Lee, K. Y., Kim, M. S., Heo, J. Y., Ku, B. M., Sun, J. M., Lee, S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2020). Regulatory (FoxP3(+)) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports, 10, 18994.","journal-title":"Scientific Reports"},{"key":"10244_CR54","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3390\/cancers15061901","volume":"15","author":"P Grell","year":"2023","unstructured":"Grell, P., Borilova, S., Fabian, P., Selingerova, I., Novak, D., Muller, P., Kiss, I., & Vyzula, R. (2023). FoxP3 expression in tumor-infiltrating lymphocytes as potential predictor of response to immune checkpoint inhibitors in patients with advanced melanoma and non-small cell lung cancer. Cancers, 15, 1901.","journal-title":"Cancers"},{"key":"10244_CR55","first-page":"880","volume":"13","author":"J Hao","year":"2020","unstructured":"Hao, J., Wang, H., Song, L., Li, S., Che, N., Zhang, S., Zhang, H., & Wang, J. (2020). Infiltration of CD8(+) FOXP3(+) T cells, CD8(+) T cells, and FOXP3(+) T cells in non-small cell lung cancer microenvironment. International Journal of Clinical and Experimental Pathology, 13, 880\u2013888.","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"10244_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Seminars in Immunology, 42, 101305.","journal-title":"Seminars in Immunology"},{"key":"10244_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116095","volume":"171","author":"S Mestiri","year":"2024","unstructured":"Mestiri, S., El-Ella, D. M. A., Fernandes, Q., Bedhiafi, T., Almoghrabi, S., Akbar, S., Inchakalody, V., Assami, L., Anwar, S., Uddin, S., Gul, A. R. Z., Al-Muftah, M., Merhi, M., Raza, A., & Dermime, S. (2024). The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers. Biomedicine & Pharmacotherapy, 171, 116095.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10244_CR58","doi-asserted-by":"crossref","unstructured":"Lopez de Rodas, M., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M., Corredor, G., Barrera, C., Behlman, D.L., Rimm, D. L., Herbst, R. S., Madabhushi, A., Riess, J. W., Velcheti, V., Hellmann, M. D., Gainor, J., & Schalper, K. A. (2022). Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. Journal for Immunotherapy of Cancer, 10.","DOI":"10.1136\/jitc-2021-004440"},{"key":"10244_CR59","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen, X., Gao, A., Zhang, F., Yang, Z., Wang, S., Fang, Y., Li, J., Wang, J., Shi, W., Wang, L., Zheng, Y., & Sun, Y. (2021). ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Theranostics, 11, 3392\u20133416.","journal-title":"Theranostics"},{"key":"10244_CR60","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., Barnitz, R. A., Bartman, C., Bengsch, B., Huang, A. C., Schenkel, J. M., Vahedi, G., Haining, W. N., Berger, S. L., & Wherry, E. J. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science (New York, N.Y.), 354, 1160\u20131165.","journal-title":"Science (New York, N.Y.)"},{"key":"10244_CR61","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2159-8290.CD-20-0962","volume":"11","author":"MF Sanmamed","year":"2021","unstructured":"Sanmamed, M. F., Nie, X., Desai, S. S., Villaroel-Espindola, F., Badri, T., Zhao, D., Kim, A. W., Ji, L., Zhang, T., Quinlan, E., Cheng, X., Han, X., Vesely, M. D., Nassar, A. F., Sun, J., Zhang, Y., Kim, T. K., Wang, J., Melero, I., \u2026 Chen, L. (2021). A burned-out CD8(+) T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer discovery, 11, 1700\u20131715.","journal-title":"Cancer discovery"},{"key":"10244_CR62","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.coi.2006.05.002","volume":"18","author":"MB Lodoen","year":"2006","unstructured":"Lodoen, M. B., & Lanier, L. L. (2006). Natural killer cells as an initial defense against pathogens. Current Opinion in Immunology, 18, 391\u2013398.","journal-title":"Current Opinion in Immunology"},{"key":"10244_CR63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. Science (New York, N.Y.), 331, 44\u201349.","journal-title":"Science (New York, N.Y.)"},{"key":"10244_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.lungcan.2018.11.038","volume":"127","author":"G Mazzaschi","year":"2019","unstructured":"Mazzaschi, G., Facchinetti, F., Missale, G., Canetti, D., Madeddu, D., Zecca, A., Veneziani, M., Gelsomino, F., Goldoni, M., Buti, S., Bordi, P., Aversa, F., Ardizzoni, A., Quaini, F., & Tiseo, M. (2019). The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer (Amsterdam, Netherlands), 127, 153\u2013163.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10244_CR65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11523-020-00712-2","volume":"15","author":"YH Cho","year":"2020","unstructured":"Cho, Y. H., Choi, M. G., Kim, D. H., Choi, Y. J., Kim, S. Y., Sung, K. J., Lee, J. C., Kim, S. Y., Rho, J. K., & Choi, C. M. (2020). Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer. Targeted oncology, 15, 241\u2013247.","journal-title":"Targeted oncology"},{"key":"10244_CR66","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-020-65666-x","volume":"10","author":"JI Youn","year":"2020","unstructured":"Youn, J. I., Park, S. M., Park, S., Kim, G., Lee, H. J., Son, J., Hong, M. H., Ghaderpour, A., Baik, B., Islam, J., Choi, J. W., Lee, E. Y., Kim, H. R., Seo, S. U., Paik, S., Yoon, H. I., Jung, I., Xin, C. F., Jin, H. T., \u2026 Kim, H. R. (2020). Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Scientific reports, 10, 9050.","journal-title":"Scientific reports"},{"key":"10244_CR67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12890-022-01951-x","volume":"22","author":"Y Yan","year":"2022","unstructured":"Yan, Y., Wang, X., Liu, C., & Jia, J. (2022). Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: A retrospective study. BMC Pulmonary Medicine, 22, 166.","journal-title":"BMC Pulmonary Medicine"},{"key":"10244_CR68","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.3390\/cancers15143592","volume":"15","author":"M Tenuta","year":"2023","unstructured":"Tenuta, M., Pandozzi, C., Sciarra, F., Campolo, F., Gelibter, A. J., Sirgiovanni, G., Cortesi, E., Lenzi, A., Isidori, A. M., Sbardella, E., & Venneri, M. A. (2023). Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: Correlation with sarcopenia. Cancers, 15, 3592.","journal-title":"Cancers"},{"key":"10244_CR69","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/1078-0432.CCR-20-0175","volume":"26","author":"J Zugazagoitia","year":"2020","unstructured":"Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K., Gettinger, S., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020). Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small cell lung cancer (NSCLC) identified using high-plex digital spatial profiling. Clinical Cancer Research, 26, 4360\u20134368.","journal-title":"Clinical Cancer Research"},{"key":"10244_CR70","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cytogfr.2014.11.003","volume":"26","author":"R Paolini","year":"2015","unstructured":"Paolini, R., Bernardini, G., Molfetta, R., & Santoni, A. (2015). NK cells and interferons. Cytokine & growth factor reviews, 26, 113\u2013120.","journal-title":"Cytokine & growth factor reviews"},{"key":"10244_CR71","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.21873\/anticanres.14251","volume":"40","author":"T Kanai","year":"2020","unstructured":"Kanai, T., Suzuki, H., Yoshida, H., Matsushita, A., Kawasumi, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., Morishita, N., Hashimoto, S., Kawahara, K., Tamura, Y., Okamoto, N., Tanaka, T., & Hirashima, T. (2020). Significance of quantitative interferon-gamma levels in non-small-cell lung cancer patients\u2019 response to immune checkpoint inhibitors. Anticancer research, 40, 2787\u20132793.","journal-title":"Anticancer research"},{"key":"10244_CR72","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1042\/EBC20230001","volume":"67","author":"CW Wong","year":"2023","unstructured":"Wong, C. W., Huang, Y. Y., & Hurlstone, A. (2023). The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy. Essays in Biochemistry, 67, 991\u20131002.","journal-title":"Essays in Biochemistry"},{"key":"10244_CR73","doi-asserted-by":"publisher","first-page":"1112409","DOI":"10.3389\/fimmu.2023.1112409","volume":"14","author":"WT Hu","year":"2023","unstructured":"Hu, W. T., Zhang, Q., Zhang, Z., He, X., Zhou, M., Guo, Y., & Wang, X. (2023). Eosinophil and IFN-\u03b3 associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. Frontiers in Immunology, 14, 1112409.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR74","doi-asserted-by":"publisher","first-page":"175883401774974","DOI":"10.1177\/1758834017749748","volume":"10","author":"N Karachaliou","year":"2018","unstructured":"Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos, M., Gil, SM Algarra., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R. (2018). Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 10, 1758834017749748.","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10244_CR75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41416-023-02285-z","volume":"129","author":"SWC Wen","year":"2023","unstructured":"Wen, S. W. C., Nederby, L., Andersen, R. F., Hansen, T. S., Nyhus, C. H., Hilberg, O., Jakobsen, A., & Hansen, T. F. (2023). NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors. British journal of cancer, 129, 135\u2013142.","journal-title":"British journal of cancer"},{"key":"10244_CR76","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/eji.202149608","volume":"52","author":"X Chen","year":"2022","unstructured":"Chen, X., Chen, Y., Xin, Z., Lin, M., Hao, Z., Chen, D., He, T., Zhao, L., Wu, D., Wu, P., & Chai, Y. (2022). Tissue-resident CD69(+) CXCR6(+) Natural Killer cells with exhausted phenotype accumulate in human non-small cell lung cancer. European Journal of Immunology, 52, 1993\u20132005.","journal-title":"European Journal of Immunology"},{"key":"10244_CR77","doi-asserted-by":"publisher","first-page":"e001054","DOI":"10.1136\/jitc-2020-001054","volume":"8","author":"J Russick","year":"2020","unstructured":"Russick, J., Joubert, P. E., Gillard-Bocquet, M., Torset, C., Meylan, M., Petitprez, F., Dragon-Durey, M. A., Marmier, S., Varthaman, A., Josseaume, N., Germain, C., Goc, J., Dieu-Nosjean, M. C., Validire, P., Fournel, L., Zitvogel, L., Bindea, G., Lupo, A., Damotte, D., \u2026 Cremer, I. (2020). Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Journal for Immunotherapy of Cancer, 8, e001054.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10244_CR78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molimm.2022.02.015","volume":"144","author":"W Zhang","year":"2022","unstructured":"Zhang, W., Zhao, Z., & Li, F. (2022). Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology, 144, 58\u201370.","journal-title":"Molecular Immunology"},{"key":"10244_CR79","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M. C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M. (2018). Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. The Journal of clinical Investigation, 128, 4654\u20134668.","journal-title":"The Journal of clinical Investigation"},{"key":"10244_CR80","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/1759-7714.13677","volume":"11","author":"MG Choi","year":"2020","unstructured":"Choi, M. G., Kim, Y. J., Lee, J. C., Rho, J. K., & Choi, C. M. (2020). Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thoracic Cancer, 11, 3337\u20133345.","journal-title":"Thoracic Cancer"},{"key":"10244_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163456","volume":"6","author":"L Fend","year":"2017","unstructured":"Fend, L., Rusakiewicz, S., Adam, J., Bastien, B., Caignard, A., Messaoudene, M., Iribarren, C., Cremer, I., Marabelle, A., Borg, C., Semeraro, M., Barraud, L., Limacher, J. M., Eggermont, A., Kroemer, G., & Zitvogel, L. (2017). Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology, 6, e1163456.","journal-title":"Oncoimmunology"},{"key":"10244_CR82","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-020-02558-z","volume":"69","author":"MP Trefny","year":"2020","unstructured":"Trefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M., Lardinois, D., L\u00e4ubli, H., Uhlenbrock, F., & Zippelius, A. (2020). PD-1(+) natural killer cells in human non-small cell lung cancer can be activated by PD-1\/PD-L1 blockade. Cancer Immunology, Immunotherapy\u202f: CII, 69, 1505\u20131517.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10244_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu, J., Zhang, L., Xia, H., Yan, Y., Zhu, X., Sun, F., Sun, L., Li, S., Li, D., Wang, J., Han, Y., Zhang, J., Bian, D., Yu, H., Chen, Y., Fan, P., Ma, Q., Jiang, G., Wang, C., & Zhang, P. (2023). Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Medicine, 15, 14.","journal-title":"Genome Medicine"},{"key":"10244_CR84","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s12094-023-03120-w","volume":"25","author":"DR Qiao","year":"2023","unstructured":"Qiao, D. R., Cheng, J. Y., Yan, W. Q., & Li, H. J. (2023). PD-L1\/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. Clinical & translational oncology\u202f: Official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 25, 2373\u20132383.","journal-title":"Clinical & translational oncology : Official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"key":"10244_CR85","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., Alvarado, M. D., Wolf, D. M., Bogunovic, D., Bhardwaj, N., Daud, A. I., Ha, P. K., Ryan, W. R., Pollack, J. L., Samad, B., \u2026 Krummel, M. F. (2018). A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nature medicine, 24, 1178\u20131191.","journal-title":"Nature medicine"},{"key":"10244_CR86","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","volume":"3","author":"B Boyerinas","year":"2015","unstructured":"Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015). Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunology Research, 3, 1148\u20131157.","journal-title":"Cancer Immunology Research"},{"key":"10244_CR87","doi-asserted-by":"publisher","first-page":"e000753","DOI":"10.1136\/esmoopen-2020-000753","volume":"5","author":"M Fasano","year":"2020","unstructured":"Fasano, M., Della Corte, C. M., Di Liello, R., Barra, G., Sparano, F., Viscardi, G., Iacovino, M. L., Paragliola, F., Famiglietti, V., Ciaramella, V., Cimmino, F., Capasso, M., Iolascon, A., Sforza, V., Morabito, A., Maiello, E., Ciardiello, F., & Morgillo, F. (2020). Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO open, 5, e000753.","journal-title":"ESMO open"},{"key":"10244_CR88","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2174\/1568026623666230201145909","volume":"23","author":"HA Lafta","year":"2023","unstructured":"Lafta, H. A., AbdulHussein, A. H., Al-Shalah, S. A. J., Alnassar, Y. S., Mohammed, N. M., Akram, S. M., Qasim, M. T., & Najafi, M. (2023). Tumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products. Current Topics in Medicinal Chemistry, 23, 1104\u20131122.","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10244_CR89","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023). Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Molecular Cancer, 22, 58.","journal-title":"Molecular Cancer"},{"key":"10244_CR90","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3389\/fimmu.2018.02858","volume":"9","author":"D Namgaladze","year":"2018","unstructured":"Namgaladze, D., Zukunft, S., Schn\u00fctgen, F., Kurrle, N., Fleming, I., Fuhrmann, D., & Br\u00fcne, B. (2018). Polarization of human macrophages by interleukin-4 does not require ATP-citrate lyase. Frontiers in Immunology, 9, 2858.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez, F. O., & Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000prime Reports, 6, 13.","journal-title":"F1000prime Reports"},{"key":"10244_CR92","first-page":"4107","volume":"22","author":"F Xu","year":"2020","unstructured":"Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020). Tumor-associated macrophages in lung cancer: Friend or foe? (Review). Molecular Medicine Reports, 22, 4107\u20134115.","journal-title":"Molecular Medicine Reports"},{"key":"10244_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100412","volume":"28","author":"T Chen","year":"2021","unstructured":"Chen, T., Liu, Y., Li, C., Xu, C., Ding, C., Chen, J., & Zhao, J. (2021). Tumor-derived exosomal circFARSA mediates M2 macrophage polarization via the PTEN\/PI3K\/AKT pathway to promote non-small cell lung cancer metastasis. Cancer Treatment and Research Communications, 28, 100412.","journal-title":"Cancer Treatment and Research Communications"},{"key":"10244_CR94","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nri3088","volume":"11","author":"T Lawrence","year":"2011","unstructured":"Lawrence, T., & Natoli, G. (2011). Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nature reviews Immunology, 11, 750\u2013761.","journal-title":"Nature reviews Immunology"},{"key":"10244_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-018-0241-4","volume":"19","author":"J Jackute","year":"2018","unstructured":"Jackute, J., Zemaitis, M., Pranys, D., Sitkauskiene, B., Miliauskas, S., Vaitkiene, S., & Sakalauskas, R. (2018). Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunology, 19, 3.","journal-title":"BMC Immunology"},{"key":"10244_CR96","doi-asserted-by":"publisher","first-page":"e003890","DOI":"10.1136\/jitc-2021-003890","volume":"10","author":"M Larroquette","year":"2022","unstructured":"Larroquette, M., Guegan, J. P., Besse, B., Cousin, S., Brunet, M., Le Moulec, S., Le Loarer, F., Rey, C., Soria, J. C., Barlesi, F., Bessede, A., Scoazec, J. Y., Soubeyran, I., & Italiano, A. (2022). Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies. J Immunother Cancer, 10, e003890.","journal-title":"J Immunother Cancer"},{"key":"10244_CR97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.08.023","volume":"136","author":"R Sumitomo","year":"2019","unstructured":"Sumitomo, R., Hirai, T., Fujita, M., Murakami, H., Otake, Y., & Huang, C. L. (2019). PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 136, 136\u2013144.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"10244_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8284","volume":"47","author":"R Sumitomo","year":"2022","unstructured":"Sumitomo, R., Huang, C. L., Fujita, M., Cho, H., & Date, H. (2022). Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer. Oncology Reports, 47, 1.","journal-title":"Oncology Reports"},{"key":"10244_CR99","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Xu, J., & Lan, H. (2019). Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. Journal of Hematology & Oncology, 12, 76.","journal-title":"Journal of Hematology & Oncology"},{"key":"10244_CR100","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00262-022-03173-w","volume":"71","author":"H Zhang","year":"2022","unstructured":"Zhang, H., Liu, Z., Wen, H., Guo, Y., Xu, F., Zhu, Q., Yuan, W., Luo, R., Lu, C., Liu, R., Gu, J., & Ge, D. (2022). Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy\u202f: CII, 71, 2511\u20132522.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10244_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","volume":"67","author":"W Li","year":"2022","unstructured":"Li, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022). Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine & Growth Factor Reviews, 67, 49\u201357.","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10244_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/imm.13646","volume":"169","author":"J Monkman","year":"2023","unstructured":"Monkman, J., Kim, H., Mayer, A., Mehdi, A., Matigian, N., Cumberbatch, M., Bhagat, M., Ladwa, R., Mueller, S. N., Adams, M. N., O\u2019Byrne, K., & Kulasinghe, A. (2023). Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer. Immunology, 169, 487\u2013502.","journal-title":"Immunology"},{"key":"10244_CR103","doi-asserted-by":"publisher","first-page":"e006433","DOI":"10.1136\/jitc-2022-006433","volume":"11","author":"MJ van Elsas","year":"2023","unstructured":"van Elsas, M. J., Labrie, C., Etzerodt, A., Charoentong, P., van StigtThans, J. J. C., Van Hall, T., & van der Burg, S. H. (2023). Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for Immunotherapy of Cancer, 11, e006433.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10244_CR104","doi-asserted-by":"publisher","first-page":"2210959","DOI":"10.1080\/2162402X.2023.2210959","volume":"12","author":"N Zheng","year":"2023","unstructured":"Zheng, N., Wang, T., Luo, Q., Liu, Y., Yang, J., Zhou, Y., Xie, G., Ma, Y., Yuan, X., & Shen, L. (2023). M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance. Oncoimmunology, 12, 2210959.","journal-title":"Oncoimmunology"},{"key":"10244_CR105","doi-asserted-by":"publisher","first-page":"e007441","DOI":"10.1136\/jitc-2023-007441","volume":"11","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Peng, W., Wang, H., Xiang, X., Ye, L., Wei, X., Wang, Z., Xue, Q., Chen, L., Su, Y., & Zhou, Q. (2023). C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. Journal for Immunotherapy of Cancer, 11, e007441.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10244_CR106","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1038\/s41467-022-31769-4","volume":"13","author":"D Lau","year":"2022","unstructured":"Lau, D., Khare, S., Stein, M. M., Jain, P., Gao, Y., BenTaieb, A., Rand, T. A., Salahudeen, A. A., & Khan, A. A. (2022). Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. Nature Communications, 13, 4053.","journal-title":"Nature Communications"},{"key":"10244_CR107","doi-asserted-by":"publisher","first-page":"e004582","DOI":"10.1136\/jitc-2022-004582","volume":"10","author":"M Harel","year":"2022","unstructured":"Harel, M., Lahav, C., Jacob, E., Dahan, N., Sela, I., Elon, Y., RavehShoval, S., Yahalom, G., Kamer, I., Zer, A., Sharon, O., Carbone, D. P., Dicker, A. P., Bar, J., & Shaked, Y. (2022). Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. The Journal for ImmunoTherapy of Cancer, 10, e004582.","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10244_CR108","first-page":"60","volume":"208","author":"Y Chao","year":"2022","unstructured":"Chao, Y., Jiang, W., Wang, X., Wang, X., Song, J., Chen, C., Zhou, J., Huang, Q., Hu, J., & Song, Y. (2022). Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. Clinical and Experimental Immunology, 208, 60\u201371.","journal-title":"Clinical and Experimental Immunology"},{"key":"10244_CR109","first-page":"S542","volume":"16","author":"ZLJ Wang","year":"2021","unstructured":"Wang, Z. L. J., Feng, A., Tian, K., Wei, Y., Wang, W., Pan, Q., Zhang, L., Wang, F., & Zhang, S. (2021). The association of patient HLA class I genotype and genomic alterations of non-small cell lung cancer. Journal of Thoracic Oncology, 16, S542.","journal-title":"Journal of Thoracic Oncology"},{"key":"10244_CR110","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.esmoop.2022.100719","volume":"7","author":"K-HPH Choi","year":"2022","unstructured":"Choi, K.-H.P.H., Lim, S. M., Cho, B. C., & Hong, S. (2022). Single-cell RNA sequencing in metastatic lung cancer uncovers the efficacy of PD-1\/PD-L1 inhibitors on immune cell population. ESMO Open, 7, 100719.","journal-title":"ESMO Open"},{"key":"10244_CR111","doi-asserted-by":"crossref","unstructured":"Ma, K. Y., Schonnesen, A. A., Brock, A., Van Den Berg, C., Eckhardt, S. G., Liu, Z., & Jiang, N. (2019). Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes. JCI Insight, 4.","DOI":"10.1172\/jci.insight.121387"},{"key":"10244_CR112","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M., Grout, J. A., Maier, B. B., Nabet, B. Y., Park, M. D., Tabachnikova, A., Chang, C., Walker, L., Lansky, A., Le Berichel, J., Troncoso, L., Malissen, N., Davila, M., Martin, J. C., Magri, G., Tuballes, K., Zhao, Z., Petralia, F., Samstein, R., \u2026 Merad, M. (2021). Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell, 39, 1594-1609 e1512.","journal-title":"Cancer Cell"},{"key":"10244_CR113","doi-asserted-by":"crossref","unstructured":"Wu, K. J. H., Rodriguez, M. L. B., Tian, Y., Tsang, S., Fradette, J. J., Gibson, L., & Gibbons, D. L. (2022). Exploring anti-PD-1 resistance mechanisms for therapeutic Targeting in NSCLC. Leading Edge of Cancer Research Symposium","DOI":"10.52519\/00094"},{"key":"10244_CR114","doi-asserted-by":"publisher","first-page":"2100060","DOI":"10.1002\/ggn2.202100060","volume":"3","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Zhang, H., Zhang, L., Li, D., Qi, M., Zhang, L., Yu, H., Wang, D., Jiang, G., Wang, X., Zhu, X., & Zhang, P. (2022). Single-cell transcriptome identifies drug-resistance signature and immunosuppressive microenvironment in metastatic small cell lung cancer. Advanced Genetics (Hoboken), 3, 2100060.","journal-title":"Advanced Genetics (Hoboken)"},{"key":"10244_CR115","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3390\/cancers14133123","volume":"14","author":"Q Ye","year":"2022","unstructured":"Ye, Q., & Guo, N. L. (2022). Single B cell gene co-expression networks implicated in prognosis, proliferation, and therapeutic responses in non-small cell lung cancer bulk tumors. Cancers (Basel), 14, 3123.","journal-title":"Cancers (Basel)"},{"key":"10244_CR116","doi-asserted-by":"publisher","first-page":"13553","DOI":"10.1007\/s00432-023-05151-w","volume":"149","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Guan, M., Zhang, X., Yu, F., & Lai, F. (2023). Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 149, 13553\u201313574.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10244_CR117","doi-asserted-by":"publisher","first-page":"e1155","DOI":"10.1002\/ctm2.1155","volume":"13","author":"H Peng","year":"2023","unstructured":"Peng, H., Wu, X., Liu, S., He, M., Xie, C., Zhong, R., Liu, J., Tang, C., Li, C., Xiong, S., Zheng, H., He, J., Lu, X., & Liang, W. (2023). Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clinical and Translational Medicine, 13, e1155.","journal-title":"Clinical and Translational Medicine"},{"key":"10244_CR118","doi-asserted-by":"publisher","first-page":"1231315","DOI":"10.3389\/fimmu.2023.1231315","volume":"14","author":"L Esparcia-Pinedo","year":"2023","unstructured":"Esparcia-Pinedo, L., Romero-Laorden, N., & Alfranca, A. (2023). Tertiary lymphoid structures and B lymphocytes: A promising therapeutic strategy to fight cancer. Frontiers in Immunology, 14, 1231315.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR119","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.annonc.2022.06.007","volume":"33","author":"M Brunet","year":"2022","unstructured":"Brunet, M., Crombe, A., Cousin, S., Vanhersecke, L., Le Loarer, F., Bessede, A., & Italiano, A. (2022). Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Annals of Oncology, 33, 1084\u20131085.","journal-title":"Annals of Oncology"},{"key":"10244_CR120","doi-asserted-by":"publisher","first-page":"e005531","DOI":"10.1136\/jitc-2022-005531","volume":"10","author":"X Sun","year":"2022","unstructured":"Sun, X., Liu, W., Sun, L., Mo, H., Feng, Y., Wu, X., Li, C., Chen, C., Li, J., Xin, Y., Zhang, Z., Wang, C., Zhang, B., & Yue, D. (2022). Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. The Journal for ImmunoTherapy of Cancer, 10, e005531.","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10244_CR121","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41416-021-01307-y","volume":"124","author":"M Rakaee","year":"2021","unstructured":"Rakaee, M., Kilvaer, T. K., Jamaly, S., Berg, T., Paulsen, E. E., Berglund, M., Richardsen, E., Andersen, S., Al-Saad, S., Poehl, M., Pezzella, F., Kwiatkowski, D. J., Bremnes, R. M., Busund, L. R., & Donnem, T. (2021). Tertiary lymphoid structure score: A promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 124, 1680\u20131689.","journal-title":"British Journal of Cancer"},{"key":"10244_CR122","doi-asserted-by":"publisher","first-page":"105002","DOI":"10.1016\/j.isci.2022.105002","volume":"25","author":"B Zheng","year":"2022","unstructured":"Zheng, B., Yang, Y., Chen, L., Wu, M., & Zhou, S. (2022). B-cell receptor repertoire sequencing: Deeper digging into the mechanisms and clinical aspects of immune-mediated diseases. iScience, 25, 105002.","journal-title":"iScience"},{"key":"10244_CR123","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00262-021-02900-z","volume":"70","author":"Y Nakahara","year":"2021","unstructured":"Nakahara, Y., Matsutani, T., Igarashi, Y., Matsuo, N., Himuro, H., Saito, H., Yamada, K., Murotani, K., Hoshino, T., Azuma, K., & Sasada, T. (2021). Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR\/ALK wild-type NSCLC treated with anti-PD-1 antibody. Cancer Immunology, Immunotherapy\u202f: CII, 70, 2881\u20132892.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10244_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.989968","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X., Wang, R., Wang, S., Wang, L., & Yu, J. (2022). Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer. Frontiers in Immunology, 13, 989968.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759217","volume":"12","author":"L Xia","year":"2021","unstructured":"Xia, L., Guo, L., Kang, J., Yang, Y., Yao, Y., Xia, W., Sun, R., Zhang, S., Li, W., Gao, Y., Chen, H., Li, Z., Yang, J., Lu, S., & Wang, Y. (2021). Predictable roles of peripheral IgM memory B cells for the responses to anti-PD-1 monotherapy against advanced non-small cell lung cancer. Frontiers in Immunology, 12, 759217.","journal-title":"Frontiers in Immunology"},{"key":"10244_CR126","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., Sznol, M., Dhodapkar, M. V., & Dhodapkar, K. M. (2018). Early B cell changes predict autoimmunity following combination immune checkpoint blockade. The Journal of Clinical Investigation, 128, 715\u2013720.","journal-title":"The Journal of Clinical Investigation"},{"key":"10244_CR127","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41467-022-30863-x","volume":"13","author":"AJ Patel","year":"2022","unstructured":"Patel, A. J., Willsmore, Z. N., Khan, N., Richter, A., Naidu, B., Drayson, M. T., Papa, S., Cope, A., Karagiannis, S. N., Perucha, E., & Middleton, G. W. (2022). Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nature Communications, 13, 3148.","journal-title":"Nature Communications"},{"key":"10244_CR128","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13287-019-1280-3","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Chu, Y., Ren, X., Xiang, H., Xi, Y., Ma, X., Zhu, K., Guo, Z., Zhou, C., Zhang, G., & Chen, B. (2019). Epidural adipose tissue-derived mesenchymal stem cell activation induced by lung cancer cells promotes malignancy and EMT of lung cancer. Stem Cell Research & Therapy, 10, 168.","journal-title":"Stem Cell Research & Therapy"},{"key":"10244_CR129","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.trecan.2022.03.001","volume":"8","author":"PE Saw","year":"2022","unstructured":"Saw, P. E., Chen, J., & Song, E. (2022). Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer, 8, 527\u2013555.","journal-title":"Trends Cancer"},{"key":"10244_CR130","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022). Cancer-associated fibroblasts and resistance to anticancer therapies: Status, mechanisms, and countermeasures. Cancer Cell International, 22, 166.","journal-title":"Cancer Cell International"},{"key":"10244_CR131","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022). Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Research, 82, 2904\u20132917.","journal-title":"Cancer Research"},{"key":"10244_CR132","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023). Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Molecular Cancer, 22, 29.","journal-title":"Molecular Cancer"},{"key":"10244_CR133","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-024-02106-8","volume":"23","author":"Z Lin","year":"2024","unstructured":"Lin, Z., Li, G., Jiang, K., Li, Z., & Liu, T. (2024). Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: Biological mechanisms to clinical significance and implications. Molecular Cancer, 23, 191.","journal-title":"Molecular Cancer"},{"key":"10244_CR134","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s13577-024-01056-z","volume":"37","author":"Y Fan","year":"2024","unstructured":"Fan, Y., & Yu, Y. (2024). Cancer-associated fibroblasts-derived exosomal METTL3 promotes the proliferation, invasion, stemness and glutaminolysis in non-small cell lung cancer cells by eliciting SLC7A5 m6A modification. Human Cell, 37, 1120\u20131131.","journal-title":"Human Cell"},{"key":"10244_CR135","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70025","volume":"28","author":"J Wu","year":"2024","unstructured":"Wu, J., Zhang, Q., Yang, Z., Xu, Y., Liu, X., Wang, X., Peng, J., Xiao, J., Wang, Y., Shang, Z., Wang, N., Li, L., Zhang, R., Zhang, W., Zhang, J., Zeng, Z., & Wu, J. (2024). CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness. Journal of Cellular and Molecular Medicine, 28, e70025.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10244_CR136","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JTO.0000000000000193","volume":"9","author":"L Song","year":"2014","unstructured":"Song, L., Smith, M. A., Doshi, P., Sasser, K., Fulp, W., Altiok, S., & Haura, E. B. (2014). Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. Journal of Thoracic Oncology, 9, 974\u2013982.","journal-title":"Journal of Thoracic Oncology"},{"key":"10244_CR137","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., Solomides, C. C., June, C. H., Pure, E., & Albelda, S. M. (2014). Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunologic Research, 2, 154\u2013166.","journal-title":"Cancer Immunologic Research"},{"key":"10244_CR138","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C. C., Restifo, N. P., & Rosenberg, S. A. (2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Journal of Experimental Medicine, 210, 1125\u20131135.","journal-title":"Journal of Experimental Medicine"},{"key":"10244_CR139","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018). Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. Journal of Hematology & Oncology, 11, 120.","journal-title":"Journal of Hematology & Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10244-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:30:15Z","timestamp":1743478215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10244-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10244"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10244-8","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"5 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27"}}